Interleukin 2 restores CD3-m chain expression but fails to generate tumour-specific lytic activity in tumour-infiltrating lymphocytes derived from human colorectal hepatic metastases
1998

Interleukin 2 and Tumor-Infiltrating Lymphocytes in Colorectal Cancer

Sample size: 19 publication Evidence: moderate

Author Information

Author(s): KF Yoong, DH Adams

Primary Institution: Liver Research Laboratories, Queen Elizabeth Hospital, Birmingham, UK

Hypothesis

Can correcting the abnormality in tumor-infiltrating lymphocytes restore anti-tumor activity in colorectal hepatic metastases?

Conclusion

Interleukin 2 can restore CD3-t expression in tumor-infiltrating lymphocytes, but it does not generate tumor-specific cytolytic activity.

Supporting Evidence

  • 12 of 19 tumor-infiltrating lymphocytes were successfully expanded in vitro.
  • CD3-positive TILs showed low levels of CD25 and CD71.
  • TILs failed to lyse autologous tumor cells despite restoration of CD3-t expression.

Takeaway

The study found that while a treatment can help immune cells in cancer patients, it doesn't make them effective against the cancer itself.

Methodology

The study involved isolating tumor-infiltrating lymphocytes from colorectal cancer patients and culturing them with interleukin 2 to assess their anti-tumor activity.

Limitations

The study did not establish tumor-specific cytolytic activity despite restoring CD3-t expression.

Participant Demographics

19 patients (9 men, 10 women) with a median age of 57 years.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication